Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5

Blood

Volumn 103, Issue 4, 2004, Pages 1211-1217

  Agrawal, Lokesh ^b   VanHorn Ali, Zainab ^b   Berger, Edward A ^b   Alkhatib, Ghalib ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; RECOMBINANT CHEMOKINE RECEPTOR CCR5; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CELL FUSION; DRUG DESIGN; EXTRACELLULAR LOOP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOTOPE LABELING; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS FUSION; VIRUS INHIBITION; VIRUS STRAIN;

EID: 0842264042     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2669     Document Type: Article

References (43)

1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998;280:1884-1888.
2. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001;70:777-810.
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
4. Alkhatib G, Combadiere C, Broder CC, et al. CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-1958.
5. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135-1148.
6. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85:1149-1158.
7. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-673.
8. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. Nature. 1996;381:661-666.
9. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
10. Agrawal L, Alkhatib G. Chemokine receptors: emerging opportunities for new anti-HIV therapies. Expert Opin Ther Targets. 2001;5:303-326.
11. Biscone MJ, Pierson TC, Doms RW. Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol. 2002;2:529-533.
12. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol. 2001;82:1807-1814.
13. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999;96:667-676.
14. Cormier EG, Persuh M, Thompson DA, et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000;97:5762-5767.
15. Farzan M, Vasilieva N, Schnitzler CE, et al. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem. 2000;275:33516-33521.
16. Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol. 2001;75:5541-5549.
17. Lazdins JK, Woods-Cook K, Walker M, Alted E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res. Hum. Retroviruses. 1990;6:1157-1161.
18. Combadiere C, Ahuja SK, Murphy PM. Additions and corrections to cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem. 1995;270:16491-16494 [erratum published in J Biol Chem. 1995;270:30235].
19. Combadiere C, Ahuja SK, Murphy PM. Additions and corrections to cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem. 1995;270:16491-16494 [erratum published in J Biol Chem. 1995;270:30235].
20. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry (Mosc). 1996;35:3362-3367.
21. Nussbaum O, Broder CC, Berger EA. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 1994;68:5411-5422.
22. Fuerst TR, Niles EG, Studier FW, Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986;83:8122-8126.
23. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J. Virol. 1996;70:5487-5494.
24. Broder CC, Kennedy PE, Michaels F, Berger EA. Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors. Gene. 1994;142:167-174.
25. Alkhatib G, Berger EA, Murphy PM, Pease JE. Determinants of HIV-1 coreceptor function on CC chemokine receptor 3: importance of both extracellular and transmembrane/cytoplasmic regions. J Biol Chem. 1997;272:20420-20426.
26. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G: the WHO and NIAID Networks for HIV Isolation and Characterization. J Virol. 1996;70:1651-1667.
27. Broder CC, Berger EA. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion. J Virol. 1993;67:913-926.
28. Bazan HA, Alkhatib G, Broder CC, Berger EA. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol. 1998;72:4485-4491.
29. Xiao X, Wu L, Stantchev TS, et al. Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci U S A. 1999;96:7496-7501.
30. Maddon PJ, Littman DR, Godfrey M, Maddon DE, Chess L, Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell. 1985;42:93-104.
31. Deng HK, Unutmaz D, Kewal Ramani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses [see comments]. Nature. 1997;388:296-300.
32. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dual tropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol. 1998;72:2509-2515.
33. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385:645-649.
34. Rucker J, Edinger AL, Sharron M, et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol. 1997;71:8999-9007.
35. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384:184-187.
36. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996;384:179-183.
37. Konishi K, Ikeda K, Achiwa K, Hoshino H, Tanaka K. Synthesis of peptides mimicking chemokine receptor CCR5 and their inhibitory effects against HIV-1 infection. Chem Pharm Bull (Tokyo). 2000;48:308-309.
38. Misumi S, Nakajima R, Takamune N, Shoji S. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. J Virol. 2001;75:11614-11620.
39. Tarasova NI, Rice WG, Michejda CJ. Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J Biol Chem. 1999;274:34911-34915.
40. Platt EJ, Kuhmann SE, Rose PP, Kabat D. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human Immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. J Virol. 2001;75:12266-12278.
41. Ross TM, Bieniasz PD, Cullen BR. Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol. 1998;72:1918-1924.
42. Abdulaev NG, Strassmaier TT, Ngo T, et al. Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity. Structure (Camb). 2002;10:515-525.
43. Yeagle PL, Salloum A, Chopra A, et al. Structures of the intradiskal loops and amino terminus of the G-protein receptor, rhodopsin. J Pept Res. 2000;55:455-465.